The effect of allocation to SGLT-2 inhibitors on risk of hospitalization for HF or cardiovascular death appeared similar irrespective of whether DM was present (het tests by DM status p=0.80 for the HF trials & 0.82 for the CKD trials). This evidence concerns the gene SLC5A2 and chronic kidney disease.